Taiwan
· Delayed Price · Currency is TWD Caliway Biopharmaceuticals Statistics
Total Valuation
Caliway Biopharmaceuticals has a market cap or net worth of TWD 75.43 billion. The enterprise value is 72.10 billion.
| Market Cap | 75.43B |
| Enterprise Value | 72.10B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Caliway Biopharmaceuticals has 139.42 million shares outstanding. The number of shares has increased by 7.61% in one year.
| Shares Outstanding | 139.42M |
| Shares Change (YoY) | +7.61% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.07% |
| Float | 139.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,011.32 |
| PB Ratio | 22.48 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -115.84 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -127.80 |
Financial Position
The company has a current ratio of 41.91, with a Debt / Equity ratio of 0.48.
| Current Ratio | 41.91 |
| Quick Ratio | 41.62 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -1,626.20 |
Financial Efficiency
Return on equity (ROE) is -29.15% and return on invested capital (ROIC) is -19.57%.
| Return on Equity (ROE) | -29.15% |
| Return on Assets (ROA) | -19.04% |
| Return on Capital (ROIC) | -19.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | 2.31 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.70% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +48.70% |
| 50-Day Moving Average | 635.36 |
| 200-Day Moving Average | 481.61 |
| Relative Strength Index (RSI) | 28.25 |
| Average Volume (20 Days) | 366,577 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Caliway Biopharmaceuticals had revenue of TWD 35.52 million and -622.43 million in losses. Loss per share was -4.71.
| Revenue | 35.52M |
| Gross Profit | 25.16M |
| Operating Income | -674.87M |
| Pretax Income | -622.43M |
| Net Income | -622.43M |
| EBITDA | -654.30M |
| EBIT | -674.87M |
| Loss Per Share | -4.71 |
Balance Sheet
The company has 3.34 billion in cash and 16.25 million in debt, giving a net cash position of 3.32 billion or 23.84 per share.
| Cash & Cash Equivalents | 3.34B |
| Total Debt | 16.25M |
| Net Cash | 3.32B |
| Net Cash Per Share | 23.84 |
| Equity (Book Value) | 3.36B |
| Book Value Per Share | 24.07 |
| Working Capital | 3.29B |
Cash Flow
In the last 12 months, operating cash flow was -550.17 million and capital expenditures -14.03 million, giving a free cash flow of -564.20 million.
| Operating Cash Flow | -550.17M |
| Capital Expenditures | -14.03M |
| Free Cash Flow | -564.20M |
| FCF Per Share | -4.05 |
Margins
| Gross Margin | 70.85% |
| Operating Margin | -1,900.25% |
| Pretax Margin | -1,752.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,588.62% |
Dividends & Yields
Caliway Biopharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.61% |
| Shareholder Yield | -7.61% |
| Earnings Yield | -0.87% |
| FCF Yield | -0.75% |
Stock Splits
The last stock split was on March 21, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Mar 21, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |